<DOC>
	<DOC>NCT01644890</DOC>
	<brief_summary>To verify the non-inferiority of NK105, a paclitaxel-incorporating micellar nanoparticle, to paclitaxel in terms of the progression-free survival in patients with metastatic or recurrent breast cancer.</brief_summary>
	<brief_title>A Phase III Study of NK105 in Patients With Breast Cancer</brief_title>
	<detailed_description>This study is a randomized, open-label, multi-national phase III study.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written informed consent of the patient signed by herself. Histologically confirmed metastatic or recurrent adenocarcinoma of the breast. Aged 20 to 74 at the time of informed consent. Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NK105, Paclitaxel, Breast cancer, Micelle</keyword>
</DOC>